{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"30.0"},{"groupId":"OG001","spread":"41","value":"48.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"53.6"},{"groupId":"OG001","spread":"44","value":"80.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Cycle 1 Day 43"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Population Pharmacokinetics (PK): Minimum observed plasma concentration of Ramucirumab.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 8 mg/kg Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle.","id":"OG000","title":"8 mg/kg Ramucirumab"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG001","title":"12 mg/kg Ramucirumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug and had evaluable PK data. Per protocol, 12 mg/kg Ramucirumab PK data were reported per dose level combining Part A and B participants.","reportingStatus":"POSTED","timeFrame":"Predose, Cycle 1 Day 1 (end of infusion (EOI), 1 hour after EOI) and Cycle 1 Day 43 (1 hour after EOI)","title":"Population Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab","type":"PRIMARY","unitOfMeasure":"microgram per milliliter (µg/mL)"}